| Schedule of goodwill recognized and impairment analysis |
Goodwill analysis in € K | | | | | | | | | | | | September 30, 2026 | | December 31, 2025 | Goodwill | | 14,016,750 | | 13,571,394 | thereof Care Delivery | | 11,634,644 | | 11,212,997 | thereof Value-Based Care | | 381,487 | | 368,663 | thereof Care Enablement | | 2,000,619 | | 1,989,734 | FME AG shareholders’ equity | | 12,792,675 | | 13,309,832 | Market capitalization | | 10,268,786 | | 11,383,815 |
Excess of recoverable amount over carrying amount in € K | | | | | | | | | | | | | | | | | | | | | | | | | | | | Care Delivery | | Value-Based Care | | Care Enablement | | | September 30, 2026 | | December 31, 2025 | | September 30, 2026 | | December 31, 2025 | | September 30, 2026 | | December 31, 2025 | Recoverable amount of CGUs | | 3,781,419 | | 6,521,602 | | 355,601 | | 172,260 | | 2,021,225 | | 2,732,309 |
Key assumptions in % | | | | | | | | | | | | | | | | | | | | | | | | | | | | Care Delivery | | Value-Based Care | | Care Enablement | | | September 30, 2026 | | December 31, 2025 | | September 30, 2026 | | December 31, 2025 | | September 30, 2026 | | December 31, 2025 | Average revenue growth in projection period (1) | | low-single-digit | | low-single-digit | | mid-single-digit | | high-single-digit | | mid-single-digit | | mid-single-digit | Average operating income growth in projection period (1) | | mid-single-digit | | mid-single-digit | | low-triple-digit | | low-triple-digit | | low-double-digit | | high-single-digit | Residual value growth | | 1.00 | | 1.00 | | 2.80 | | 2.80 | | 1.00 | | 1.00 | Pre-tax WACC | | 9.64 | | 8.90 | | 7.97 | | 8.53 | | 8.55 | | 8.43 | After-tax WACC | | 7.68 | | 7.21 | | 6.68 | | 7.20 | | 6.95 | | 6.42 |
| (1) | For CGUs Care Delivery and Care Enablement, a projection period of ten years is used. For CGU Value-Based Care, a projection period of five years is used, given the nascent nature of the business. |
Sensitivity analysis(1) Change in percentage | | | | | | | | | | | | | | | | | | | | | | | | | | | | Care Delivery | | Value-Based Care | | Care Enablement | | | September 30, 2026 | | December 31, 2025 | | September 30, 2026 | | December 31, 2025 | | September 30, 2026 | | December 31, 2025 | Pre-tax WACC | | 1.83 | | 2.69 | | 3.50 | | 1.71 | | 1.72 | | 2.02 | After-tax WACC | | 1.44 | | 2.11 | | 2.74 | | 1.32 | | 1.36 | | 1.41 | Residual value growth | | (5.63) | | (8.53) | | (5.39) | | (2.36) | | (4.19) | | (4.74) | Operating income margin of each projection year | | (2.18) | | (3.18) | | (0.87) | | (0.41) | | (2.25) | | (2.62) |
| (1) | The sensitivity analysis is based upon the goodwill impairment tests performed as of September 30, 2026 and December 31, 2025. |
|
| Schedule of reclassifications |
| | | | | | | January 1, 2025 | | December 31, 2025 | Current income tax refundable | | 248,668 | | 126,197 | Other current assets (1) | | 584,180 | | 410,834 | Non-current income tax refundable | | 62,361 | | 92,051 | Other non-current assets | | 135,964 | | 126,174 | Current provisions | | 448,368 | | 431,370 | Other current liabilities (1) | | 1,079,077 | | 1,039,743 | Non-current provisions | | 196,516 | | 173,351 | Other non-current liabilities | | 177,647 | | 147,563 |
| (1) | As of January 1, 2025, assets held for sale and liabilities directly associated with assets held for sale in the amount of €161,013 and €27,511 are included in “Other current assets” and “Other current liabilities.” respectively. |
|